MX2023009567A - Formulaciones de polipeptidos de union a dr5. - Google Patents

Formulaciones de polipeptidos de union a dr5.

Info

Publication number
MX2023009567A
MX2023009567A MX2023009567A MX2023009567A MX2023009567A MX 2023009567 A MX2023009567 A MX 2023009567A MX 2023009567 A MX2023009567 A MX 2023009567A MX 2023009567 A MX2023009567 A MX 2023009567A MX 2023009567 A MX2023009567 A MX 2023009567A
Authority
MX
Mexico
Prior art keywords
formulations
binding polypeptides
polypeptides
binding
Prior art date
Application number
MX2023009567A
Other languages
English (en)
Inventor
Brian Lobo
Ashraf Amanullah
Original Assignee
Inhibrx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inhibrx Inc filed Critical Inhibrx Inc
Publication of MX2023009567A publication Critical patent/MX2023009567A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proveen en la presente formulaciones de polipéptidos de unión a DR5; se proveen también usos de los polipéptidos de unión a DR5.
MX2023009567A 2021-02-19 2022-02-18 Formulaciones de polipeptidos de union a dr5. MX2023009567A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163151131P 2021-02-19 2021-02-19
PCT/US2022/016935 WO2022178223A1 (en) 2021-02-19 2022-02-18 Formulations of dr5 binding polypeptides

Publications (1)

Publication Number Publication Date
MX2023009567A true MX2023009567A (es) 2023-08-22

Family

ID=80683254

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023009567A MX2023009567A (es) 2021-02-19 2022-02-18 Formulaciones de polipeptidos de union a dr5.

Country Status (10)

Country Link
EP (1) EP4294842A1 (es)
JP (1) JP2024506931A (es)
KR (1) KR20230147662A (es)
CN (1) CN117098778A (es)
AU (1) AU2022223977A1 (es)
CA (1) CA3208641A1 (es)
IL (1) IL305265A (es)
MX (1) MX2023009567A (es)
TW (1) TW202245839A (es)
WO (1) WO2022178223A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023196943A1 (en) * 2022-04-08 2023-10-12 Inhibrx, Inc. Dr5 agonist and plk1 inhibitor or cdk inhibitor combination therapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
AU760562B2 (en) 1997-12-05 2003-05-15 Scripps Research Institute, The Humanization of murine antibody
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
ES2393555T3 (es) 2003-10-22 2012-12-26 Keck Graduate Institute Métodos para la síntesis de polipéptidos hetero-multiméricos en levaduras usando una estrategia de apareamiento haploide.
WO2005097832A2 (en) 2004-03-31 2005-10-20 Genentech, Inc. Humanized anti-tgf-beta antibodies
CA2991634A1 (en) * 2015-07-16 2017-01-19 Inhibrx Lp Multivalent and multispecific dr5-binding fusion proteins

Also Published As

Publication number Publication date
EP4294842A1 (en) 2023-12-27
WO2022178223A1 (en) 2022-08-25
KR20230147662A (ko) 2023-10-23
CA3208641A1 (en) 2022-08-25
AU2022223977A9 (en) 2023-08-24
JP2024506931A (ja) 2024-02-15
TW202245839A (zh) 2022-12-01
IL305265A (en) 2023-10-01
CN117098778A (zh) 2023-11-21
AU2022223977A1 (en) 2023-08-17

Similar Documents

Publication Publication Date Title
MX2021010160A (es) Preparaciones de membrana bacteriana.
NZ761434A (en) Cytokine conjugates for the treatment of autoimmune diseases
MX2020008542A (es) Composiciones y métodos para el suministro de proteínas membranales.
MX2021013417A (es) Polipeptidos de union a la proteina del miembro a de la familia 12 del dominio de lectina tipo c (clec12a) y sus usos.
MX2021002970A (es) Proteinas de union a nkg2d, cd16 y un antigeno asociado a tumor.
EP4273258A3 (en) Proteins binding her2, nkg2d and cd16
MX2019009566A (es) Proteinas de union a bcma, nkg2d y cd16.
MX2021014286A (es) Proteinas multiespecificas.
AU2020226864A8 (en) Lachnospiraceae Bacterium ND2006 Cas12a mutant genes and polypeptides encoded by same
ZA202106602B (en) Claudin 6 antibodies and uses thereof
MX2020002036A (es) Proteinas de union a nkg2d, cd16 y un antigeno asociado al tumor.
EP4233880A3 (en) Hnf4a sarna compositions and methods of use
MX2018000395A (es) Proteinas y composiciones inmunizantes que contienen proteinas de klebsiella y metodos de uso.
MX2021013416A (es) Polipeptidos de union al antigeno cd33 y sus usos.
AU2018273250A1 (en) A protein binding NKG2D, CD16 and a tumor-associated antigen
MX2019009943A (es) Proteínas que se unen a gd2, nkg2d y cd16.
MX2020008125A (es) Composiciones que comprenden berberina.
MX2021006674A (es) Composiciones para estabilizar bacterias y usos de las mismas.
WO2020123795A3 (en) Anellosomes for delivering protein replacement therapeutic modalities
PH12021550102A1 (en) Cardiosafe antidiabetic therapy
AU2019321490A8 (en) Ox40-binding polypeptides and uses thereof
MX2021006515A (es) Composiciones de methylobacterium para mejorar el rendimiento del maíz.
MX2021016050A (es) Formulaciones transdermicas.
MX2021015761A (es) Polipeptidos.
MX2019009847A (es) Proteínas que se unen a cd123, nkg2d y cd16.